Stock News

EPS for Onconova Therapeutics, Inc. (ONTX) Expected At $-0.05

Onconova Therapeutics, Inc. (NASDAQ:ONTX) Logo

Analysts expect Onconova Therapeutics, Inc. (NASDAQ:ONTX) to report $-0.05 EPS on November, 8.They anticipate $0.66 EPS change or 92.96 % from last quarter’s $-0.71 EPS. After having $-0.08 EPS previously, Onconova Therapeutics, Inc.’s analysts see -37.50 % EPS growth. The stock increased 1.07% or $0.06 during the last trading session, reaching $5.65. About 62,230 shares traded. Onconova Therapeutics, Inc. (NASDAQ:ONTX) has declined 69.63% since October 24, 2017 and is downtrending. It has underperformed by 85.25% the S&P500.

Onconova Therapeutics, Inc. (NASDAQ:ONTX) Ratings Coverage

Among 2 analysts covering Onconova Therapeutics (NASDAQ:ONTX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Onconova Therapeutics had 2 analyst reports since May 2, 2018 according to SRatingsIntel. The stock of Onconova Therapeutics, Inc. (NASDAQ:ONTX) earned “Buy” rating by Maxim Group on Wednesday, May 2. H.C. Wainwright maintained the shares of ONTX in report on Tuesday, May 15 with “Buy” rating.

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. The company has market cap of $32.04 million. The company's clinical-stage product candidates include Rigosertib IV, which is in Phase III clinical trials for patients with higher risk myelodysplastic syndromes ; Rigosertib oral in combination with azacitidine that is in Phase II clinical trials for patients with MDS and acute myelogenous leukemia; and Rigosertib oral, which is in Phase II clinical trials for patients with lower risk MDS. It currently has negative earnings. The Company’s clinical-stage product candidates also comprise Briciclib, which is in Phase I multisite dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes.

More recent Onconova Therapeutics, Inc. (NASDAQ:ONTX) news were published by: which released: “Onconova Therapeutics to Present Update at the 2018 BIO Investor Forum in San Francisco” on October 10, 2018. Also published the news titled: “Onconova Therapeutics Announces Reverse Stock Split” on September 25, 2018.‘s news article titled: “Onconova Therapeutics Announces Issuance of a New US Patent for Rigosertib” with publication date: October 17, 2018 was also an interesting one.

Onconova Therapeutics, Inc. (NASDAQ:ONTX) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *